Clinical Trials at USC

3 Results for

Study Title	Principal Investigator
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS) Dose levels for the study's second stage will be based on safety and pharmacokinetics. Not recruiting \| Myelodysplastic Syndromes (MDS) \| Multisite View full trial information >>	Mohammad Azab
A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone Not recruiting \| Myelodysplastic Syndromes (MDS) \| Multisite View full trial information >>	Guillermo Garcia-Manero
A Phase 1b/2 Study To Evaluate The Safety And Efficacy Of Pf-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose Ara-c Or Decitabine In Patients With Acute Myeloid Leukemia Or High-risk Myelodysplastic Syndrome Not recruiting \| Leukemia \| Multisite View full trial information >>	Pfizer Center